Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.
Published
Journal Article
PURPOSE: Extrahepatic cholangiocarcinoma is a rare malignancy. Despite radical resection, survival remains poor, with high rates of local and distant failure. To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy. METHODS AND MATERIALS: A total of 45 patients (13 with proximal and 32 with distal disease) underwent resection plus radiotherapy (median dose, 50.4 Gy). All but 1 patient received concurrent fluoropyrimidine-based chemotherapy. The median follow-up was 30 months for all patients and 40 months for survivors. RESULTS: Of the 45 patients, 33 underwent adjuvant radiotherapy, and 12 were treated neoadjuvantly. The 5-year actuarial overall survival, disease-free survival, metastasis-free survival, and locoregional control rates were 33%, 37%, 42%, and 78%, respectively. The median survival was 34 months. No patient died perioperatively. Patient age
Full Text
Duke Authors
- Czito, Brian Gary
- Hurwitz, Herbert Ira
- Morse, Michael Aaron
- Pappas, Theodore N.
- Willett, Christopher G.
Cited Authors
- Nelson, JW; Ghafoori, AP; Willett, CG; Tyler, DS; Pappas, TN; Clary, BM; Hurwitz, HI; Bendell, JC; Morse, MA; Clough, RW; Czito, BG
Published Date
- January 1, 2009
Published In
Volume / Issue
- 73 / 1
Start / End Page
- 148 - 153
PubMed ID
- 18805651
Pubmed Central ID
- 18805651
Electronic International Standard Serial Number (EISSN)
- 1879-355X
Digital Object Identifier (DOI)
- 10.1016/j.ijrobp.2008.07.008
Language
- eng
Conference Location
- United States